Why is comprehensive genomic profiling not routinely performed at the time of initial prostate cancer diagnosis to identify castration‑resistant disease?

Why Genetic Testing Is Not Performed at Initial Diagnosis

Genetic testing is not routinely performed at initial prostate cancer diagnosis because the therapeutic targets (PARP inhibitors, platinum agents) are only FDA-approved and clinically validated for metastatic castration-resistant prostate cancer (mCRPC), not for localized disease. 1

The Evidence-Based Rationale

Current Guideline Recommendations

The 2025 ASCO guidelines explicitly recommend germline and somatic genomic testing for all patients with metastatic prostate cancer, not at initial diagnosis of localized disease 1. This distinction is critical because:

• Therapeutic actionability drives testing timing: The strongest evidence for genomic testing comes from trials like PROfound, which demonstrated overall survival benefit with olaparib (a PARP inhibitor) specifically in mCRPC patients with homologous recombination deficiency (HRD), particularly BRCA1/2 alterations 1

• Multiple phase III trials (TALAPRO-2, MAGNITUDE, PROpel, PROfound) all enrolled metastatic castration-resistant patients, not newly diagnosed localized disease 1

Why Testing at Diagnosis Lacks Clinical Utility

For localized prostate cancer, the 2020 ASCO guidelines explicitly state that molecular biomarkers should NOT be routinely used because:

1. Their ability to improve outcomes (quality of life, metastasis risk, mortality) has not been prospectively validated 2

2. The ProtecT trial showed relatively low rates of metastases or prostate cancer-specific mortality with active monitoring alone, meaning additional prognostic information may only benefit a narrow subset of patients 2

3. Treatment recommendations should not be made based on prognostic-only biomarkers - genomic findings must have predictive therapeutic value 1

When Genomic Testing Becomes Appropriate

The Clinical Trigger Points

Testing should occur when disease reaches the metastatic state because:

• This is when PARP inhibitors, platinum-based chemotherapy, and immune checkpoint inhibitors (for MMRd/MSI-H/TMB-H) become treatment options 1

• The ASCO panel recommends testing at metastatic diagnosis, and considering repeat testing when significant clinical status changes occur (e.g., progression to castration resistance) 1

The Biological Evolution

Research demonstrates that genomic alterations evolve across disease states:

• TP53 and BRCA2 alterations arise early in tumors that eventually metastasize 3
• APC alterations are enriched in metastatic tumors 3
• ATM alterations are specifically enriched in castration-resistant disease 3

This temporal heterogeneity means testing at diagnosis may miss therapeutically relevant alterations that emerge during disease progression 3, 4.

The Exception: Germline Testing Considerations

Germline testing (not comprehensive somatic profiling) may be considered earlier for specific high-risk presentations, though this is distinct from routine comprehensive genomic profiling:

• NCCN recommends germline testing for high-risk or metastatic disease regardless of family history 5
• Germline BRCA2 mutations confer hereditary cancer risk requiring family cascade testing 1
• However, this addresses familial risk assessment, not immediate treatment selection for localized disease

Common Pitfalls to Avoid

1. Do not confuse prognostic with predictive biomarkers: Tests like Decipher, Oncotype DX, and Prolaris provide prognostic information for localized disease but do not predict response to specific therapies 2

2. Avoid testing when results won't change management: In localized disease, standard risk stratification (PSA, Gleason grade, clinical stage) adequately guides treatment decisions between surgery, radiation, and active surveillance 2

3. Recognize cost-effectiveness concerns: Comprehensive genomic profiling costs thousands of dollars 2 and should be reserved for when results directly inform therapeutic choices

The Real-World Implementation Gap

Even in metastatic disease where testing is guideline-recommended, underuse of genetic testing persists 6. Barriers include:

• Limited access to genetic counseling
• Cost considerations
• Lack of clear implementation pathways in community practice 1, 6

Testing at initial diagnosis would compound these access issues without providing therapeutic benefit for the vast majority of patients with localized disease.

Bottom Line Algorithm

Test genomically when:

• Disease is metastatic (hormone-sensitive or castration-resistant)
• Patient is a candidate for systemic therapy
• Life expectancy exceeds 6 months
• Results will inform treatment selection (PARP inhibitors, platinum agents, immunotherapy) 1

Do not test routinely when:

• Disease is localized
• Standard risk stratification adequately guides management
• No therapeutic decision hinges on genomic results 2